Depatuxizumab Mafodotin provides an EGFR-targeting antibody-drug conjugate (ADC) for cancer and oncology research. It combines an EGFR-directed monoclonal antibody with monomethyl auristatin F (MMAF), specifically supporting studies of EGFR-positive tumors and targeted cancer therapeutics.
Key Features and Benefits
- EGFR-Targeting ADC: Combines an EGFR-directed monoclonal antibody with the cytotoxic payload MMAF for targeted cancer research.
- EGFR Recognition: Supports studies of EGFR expression, antibody binding, internalization, and tumor-targeting mechanisms.
- MMAF Payload: Contains monomethyl auristatin F, a potent microtubule-disrupting agent used in ADC research.
- Targeted Payload Delivery: Supports investigation of antibody-mediated MMAF delivery specifically to EGFR-expressing cancer cells.
- Microtubule Disruption: MMAF inhibits microtubule dynamics, specifically supporting studies of ADC-mediated cytotoxic mechanisms.
- Glioblastoma Relevance: Supports research involving EGFR-amplified and EGFR-altered glioblastoma models.
- ADC Research Platform: Enables investigation of target engagement, cellular uptake, payload activity, and ADC mechanisms.
- Cancer Research: Supports studies of EGFR-targeted strategies across relevant tumor models.
Applications
- Glioblastoma Research: Supports studies of EGFR-targeted ADC approaches in glioblastoma and related experimental models.
- EGFR-Positive Cancer Research: Useful for studying tumors with elevated or altered EGFR expression.
- ADC Research: Supports investigation of antibody targeting, internalization, payload delivery, and cytotoxic activity.
- EGFR Research: Especially useful for studying EGFR expression, receptor targeting, and antibody-mediated cellular interactions.
- Targeted Cancer Therapy Research: Supports investigation of antibody-mediated delivery of cytotoxic payloads to cancer cells.
- Cell-Based Cancer Assays: Useful for evaluating ADC binding, internalization, cytotoxic response, and target-dependent activity.
- Mechanism-of-Action Studies: Supports investigation of EGFR targeting and MMAF-mediated microtubule disruption.
- Comparative ADC Research: Useful for comparing targeting strategies, linkers, payloads, and ADC performance.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures specifically for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Depatuxizumab Mafodotin combines EGFR-directed targeting with the cytotoxic MMAF payload for targeted cancer research and specifically supports glioblastoma, EGFR-positive cancer, ADC, and targeted drug delivery studies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
